Hims & Hers Health (NYSE:HIMS) Insider Deborah Autor Sells 7,054 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Deborah Autor sold 7,054 shares of Hims & Hers Health stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Hims & Hers Health Trading Down 0.7%

Hims & Hers Health stock opened at $34.74 on Friday. The company has a market cap of $7.91 billion, a price-to-earnings ratio of 64.33, a P/E/G ratio of 6.91 and a beta of 2.41. The firm has a 50-day moving average of $42.22 and a 200-day moving average of $48.68. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. Hims & Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same quarter in the previous year, the company posted $0.32 EPS. The business’s revenue was up 49.2% on a year-over-year basis. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has approved a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 4.5% during the third quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock worth $1,107,062,000 after buying an additional 844,991 shares in the last quarter. Capital World Investors increased its stake in Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after acquiring an additional 223,892 shares during the period. Farallon Capital Management LLC lifted its position in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. State Street Corp grew its holdings in shares of Hims & Hers Health by 1.9% during the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock worth $406,865,000 after purchasing an additional 132,384 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Hims & Hers Health by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock worth $236,622,000 after purchasing an additional 71,593 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HIMS. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. UBS Group set a $32.00 price objective on Hims & Hers Health in a research report on Tuesday, November 4th. Barclays started coverage on Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 target price on the stock. Leerink Partnrs upgraded Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $45.50.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.